Insider Selling: Cytokinetics (NASDAQ:CYTK) EVP Sells 4,935 Shares of Stock

Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Sung Lee sold 4,935 shares of the business’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $62.15, for a total transaction of $306,710.25. Following the completion of the transaction, the executive vice president owned 87,127 shares in the company, valued at $5,414,943.05. The trade was a 5.36% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Cytokinetics Stock Up 0.1%

Shares of Cytokinetics stock traded up $0.06 during trading on Wednesday, reaching $62.19. 1,983,803 shares of the stock were exchanged, compared to its average volume of 1,895,650. The stock’s fifty day moving average is $63.86 and its 200 day moving average is $60.93. The firm has a market cap of $7.66 billion, a price-to-earnings ratio of -9.52 and a beta of 0.56. Cytokinetics, Incorporated has a 1 year low of $29.31 and a 1 year high of $70.98.

Cytokinetics (NASDAQ:CYTK) last announced its quarterly earnings results on Tuesday, February 24th. The biopharmaceutical company reported ($1.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.48) by ($0.02). The company had revenue of $17.76 million during the quarter, compared to the consensus estimate of $8.02 million. Cytokinetics’s revenue for the quarter was up 4.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.26) EPS. Equities analysts forecast that Cytokinetics, Incorporated will post -5.24 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages recently commented on CYTK. Needham & Company LLC upped their target price on Cytokinetics from $84.00 to $85.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. Barclays began coverage on shares of Cytokinetics in a report on Wednesday, January 28th. They issued an “overweight” rating and a $87.00 price target on the stock. B. Riley Financial boosted their price objective on shares of Cytokinetics from $90.00 to $108.00 and gave the company a “buy” rating in a research report on Wednesday, January 21st. UBS Group upped their price objective on shares of Cytokinetics from $61.00 to $69.00 and gave the stock a “neutral” rating in a report on Friday, March 6th. Finally, Truist Financial raised their target price on shares of Cytokinetics from $84.00 to $92.00 and gave the stock a “buy” rating in a research report on Tuesday, February 3rd. Seventeen investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $89.89.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. EverSource Wealth Advisors LLC grew its stake in shares of Cytokinetics by 723.7% in the second quarter. EverSource Wealth Advisors LLC now owns 766 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 673 shares during the last quarter. Kemnay Advisory Services Inc. bought a new position in shares of Cytokinetics during the fourth quarter valued at $27,000. Kestra Advisory Services LLC purchased a new position in shares of Cytokinetics in the 4th quarter worth about $29,000. Quarry LP purchased a new position in shares of Cytokinetics in the 3rd quarter worth about $30,000. Finally, TD Waterhouse Canada Inc. bought a new position in Cytokinetics in the 4th quarter worth about $32,000.

Key Cytokinetics News

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Mizuho raised its price target on CYTK to $100 and kept an outperform rating, signaling strong upside versus the current price and supporting bullish investor expectations. Mizuho raises PT to $100
• Positive Sentiment: JPMorgan nudged its target up from $74 to $75 and maintains an overweight/positive stance, reinforcing the buy-side view. JPMorgan raises PT to $75
• Positive Sentiment: Barclays reiterated a Buy rating on CYTK, adding to a broad base of favorable analyst coverage and a consensus price-target materially above the current level. Barclays keeps Buy rating
• Neutral Sentiment: Cytokinetics granted options (8,628 shares) and 5,719 RSUs as inducements to five new hires — standard hiring compensation but modestly dilutive over time. Inducement grants announcement
• Neutral Sentiment: Coverage and valuation pieces (including assessments after MYQORZO trial data) keep attention on the drug pipeline; results and safety updates will remain key catalysts. MYQORZO valuation assessment
• Negative Sentiment: Significant insider selling: CEO Robert Blum sold 36,601 shares (~$2.27M at ~\$62.15). Large insider disposals can signal liquidity needs or rebalancing and may pressure sentiment. CEO Form 4
• Negative Sentiment: Other senior executives sold notable blocks this week (EVP Fady I. Malik: 12,033 shares; EVP Andrew Callos: multiple sales including 1,930 and earlier lots; EVP Sung Lee: 4,935 shares), representing single-digit percentage ownership reductions—adds to selling narrative. EVP Form 4s

About Cytokinetics

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.